ライフサイエンスコーパス: HIV-associated nephropathy

1 haracterized by a proliferative phenotype in HIV-associated nephropathy.

2 thological changes leading to proteinuria in HIV-associated nephropathy.

3 ts with CKD, irrespective of the presence of HIV-associated nephropathy.

4 loss of podocytes are important features of HIV-associated nephropathy.

5 f HIV-infected patients who have evidence of HIV-associated nephropathy.

6 s been shown to change the course of classic HIV-associated nephropathy.

7 s, immune-mediated glomerulonephritides, and HIV-associated nephropathy.

8 renal functional and pathologic outcomes of HIV-associated nephropathy.

9 n of renal epithelium in the pathogenesis of HIV-associated nephropathy.

10 A in renal epithelial cells of patients with HIV-associated nephropathy.

11 alleles are at very high risk for developing HIV-associated nephropathy.

12 sy is essential to differentiate HCV-GD from HIV-associated nephropathy.

13 nal disease that can be easily confused with HIV-associated nephropathy.

14 feature discovery in the Tg26 mouse model of HIV-associated nephropathy.

15 elial cells in polycystic kidney disease and HIV-associated nephropathy.

16 idney injury, polycystic kidney disease, and HIV-associated nephropathy.

17 ding rejection, opportunistic infection, and HIV-associated nephropathy.

18 erapy, there has been a dramatic decrease in HIV-associated nephropathy.

19 athogenesis of human immunodeficiency virus (HIV)-associated nephropathy.

20 6 patients with CKD (96.7%; 38 patients with HIV-associated nephropathy, 39 patients with HIV-positiv

21 Overall, 79% of patients with HIV-associated nephropathy and 2% of population controls

22 role of APOL1 variants in 120 patients with HIV-associated nephropathy and CKD and 108 controls from

23 APOL1 variants are associated with HIV-associated nephropathy and FSGS in African Americans

24 The rise in the number of patients with HIV-associated nephropathy and HIV-infection with end-st

25 ding focal and segmental glomerulosclerosis, HIV-associated nephropathy and hypertensive nephrosclero

26 ell as in kidney biopsies from patients with HIV-associated nephropathy and idiopathic focal segmenta

27 se in the two APOL1 transgenic mouse models, HIV-associated nephropathy and IFN-gamma administration.

28 Both HIV-associated nephropathy and immune complex kidney dis

29 explain much of the increased risk for FSGS, HIV-associated nephropathy, and hypertension-attributed

30 interval, 18 to 912; P<0.001) of developing HIV-associated nephropathy compared with HIV-positive co

31 rker Ki-67 in collapsing idiopathic FSGS and HIV-associated nephropathy compared with minimal change

32 Allograft outcomes (time to first rejection, HIV-associated nephropathy, graft failure, or death) wer

33 HIV-associated nephropathy has a characteristic patholog

34 for improved renal survival of patients with HIV-associated nephropathy has become more realistic wit

35 The development of HIV-associated nephropathy has been definitively linked

36 Historically, HIV-associated nephropathy has been the predominant caus

37 fect of fosinopril, 10 mg by mouth daily, in HIV-associated nephropathy (HIV-AN).

38 hose cells contributes to the development of HIV associated nephropathy (HIVAN) in untreated individu

39 n-embedded renal biopsies from patients with HIV-associated nephropathy (HIVAN) (n = 13), HIV-associa

40 c focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy (HIVAN) and end-stage kidney

41 well as in renal biopsies from patients with HIV-associated nephropathy (HIVAN) and FSGS.

42 The glomerular lesions of HIV-associated nephropathy (HIVAN) are associated with t

43 tubular epithelial cells from patients with HIV-associated nephropathy (HIVAN) express HIV-1 transcr

44 HIV-associated nephropathy (HIVAN) is a major cause of H

45 HIV-associated nephropathy (HIVAN) is a progressive glom

46 HIV-associated nephropathy (HIVAN) is a rapidly progress

47 HIV-associated nephropathy (HIVAN) is characterized by c

48 Renal parenchymal injury in HIV-associated nephropathy (HIVAN) is characterized by e

49 The collapsing glomerulopathy of HIV-associated nephropathy (HIVAN) is characterized by p

50 HIV-associated nephropathy (HIVAN) is now the third lead

51 R inhibition by compound C16 ameliorates the HIV-associated nephropathy (HIVAN) kidney phenotype in t

52 troviral therapy, kidney diseases other than HIV-associated nephropathy (HIVAN) predominate in HIV-in

53 hromosome/APOL1 transgenic mice crossed with HIV-associated nephropathy (HIVAN) Tg26 mice and bacteri

54 hology in chronic kidney diseases, including HIV-associated nephropathy (HIVAN) that ultimately progr

55 Classic and suspected HIV-associated nephropathy (HIVAN) were identified in 3

56 y, we hypothesized that HIV-1-induced occult HIV-associated nephropathy (HIVAN) would become apparent

57 , focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy (HIVAN), and hypertensive nep

58 on is a prominent histopathologic feature of HIV-associated nephropathy (HIVAN), but its pathogenesis

59 The classic kidney disease of HIV infection, HIV-associated nephropathy (HIVAN), is an aggressive for

60 focal segmental glomerulosclerosis (FSGS) of HIV-associated nephropathy (HIVAN), podocytes exhibit a

61 genesis of several renal diseases, including HIV-associated nephropathy (HIVAN), the most common caus

62 y has a critical role in the pathogenesis of HIV-associated nephropathy (HIVAN).

63 -nine-fold higher odds (95% CI 13 to 68) for HIV-associated nephropathy (HIVAN).

64 resembling those in human disease, including HIV-associated nephropathy (HIVAN).

65 important components of the pathogenesis of HIV-associated nephropathy (HIVAN).

66 apid decline in kidney function characterize HIV-associated nephropathy (HIVAN).

67 odocytes in the collapsing glomerulopathy of HIV-associated nephropathy (HIVAN).

68 to the pathogenesis of glomerular disease in HIV-associated nephropathy (HIVAN).

69 a central role in the glomerular disease of HIV-associated nephropathy (HIVAN).

70 IV- I develop renal disease resembling human HIV-associated nephropathy (HIVAN).

71 iscent of tubular injuries observed in human HIV-associated nephropathy (HIVAN).

72 resembling that seen in human primary CG and HIV-associated nephropathy (HIVAN).

73 izing HIV-positive donors, the recurrence of HIV-associated nephropathy in the graft kidney is an iss

74 oinfection, cardiovascular disease risk, and HIV-associated nephropathy increasingly prompt earlier t

75 Human immunodeficiency virus (HIV)-associated nephropathy is a significant cause of mo

76 HIV-associated nephropathy is a clinicopathologic entity

77 HIV-associated nephropathy is a unique pattern of sclero

78 HIV-associated nephropathy is characterized by renal pod

79 HIV-associated nephropathy is infrequently cited as a co

80 to have focal segmental glomerulosclerosis, HIV-associated nephropathy, or ESRD, prospective studies

81 erosis (FSGS), including idiopathic FSGS and HIV-associated nephropathy, podocytes undergo characteri

82 observed in the kidneys of a mouse model of HIV-associated nephropathy (Tg26 mice).

83 As a result, HIV-associated nephropathy, the classic HIV-driven kidne

84 In animal models of HIV-associated nephropathy, the expression of HIV regula

85 contrast, in collapsing idiopathic FSGS and HIV-associated nephropathy, there was disappearance of a

86 suggests a shift in the etiology of CKD from HIV-associated nephropathy toward other etiologies.

87 Typical lesions of human HIV-associated nephropathy were undetectable.

88 ely, however, that by the end of the decade, HIV-associated nephropathy will be the third leading cau